Director William G. Kaelin Jr. filed a Form 4 with the SEC on November 17, 2026, disclosing an acquisition of Eli Lilly common stock on November 16, 2026.
Key Highlights
- Reporting person: William G. Kaelin Jr., listed as a Director of Eli Lilly & Co (NYSE:LLY)
- Transaction date: November 16, 2026
- Shares acquired: 167.6364 shares of common stock, coded as an acquisition (A)
- Price per share: $1,431.67
- Resulting ownership: 22,139.3689 shares of common stock held directly following the transaction
- No derivative securities were reported in Table II of the filing
Kaelin's November 2026 Common Stock Acquisition at Eli Lilly
According to the filing, William G. Kaelin Jr., identified as a Director of Eli Lilly & Co (NYSE:LLY), acquired 167.6364 shares of the company's common stock on November 16, 2026. The transaction was recorded with an acquisition code (A) in Table I of the Form 4. The price reported for the transaction was $1,431.67 per share.
Following the reported transaction, the filing discloses that Kaelin directly beneficially owned 22,139.3689 shares of Eli Lilly common stock. The filing does not report any derivative securities acquired, disposed of, or beneficially owned, leaving Table II blank. The Form 4 was signed by Jonathan Groff on behalf of William G. Kaelin Jr. pursuant to an authorization on file, and was filed on November 17, 2026.
The filing does not indicate whether the transaction was made pursuant to a Rule 10b5-1(c) plan, as the corresponding checkbox on the form was not checked. The form was filed by one reporting person, and no amendment date is listed, indicating this is not a correction to a prior filing.
What Was Disclosed
Director William G. Kaelin Jr. reported the acquisition of 167.6364 shares of Eli Lilly & Co common stock at $1,431.67 per share on November 16, 2026, bringing his directly held total to 22,139.3689 shares, according to the Form 4 filed November 17, 2026.




Please wait processing your request...